CCL2 and neoplasm: In addition to PF-04136309 and CCX872, Carlumab (CNTO88), a human anti-CCL2 IgG1κ monoclonal antibody (mAb) was evaluated in patients with solid tumors and showed some preliminary anti-tumor activity.